Jazz Pharmaceuticals (NASDAQ:JAZZ) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $185.92, a high estimate of $210.00, and a low estimate of $150.00. Surpassing the previous average price target of $178.75, the current average has increased by 4.01%.

Diving into Analyst Ratings: An In-Depth Exploration

A clear picture of Jazz Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Jazz Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Jazz Pharmaceuticals analyst ratings.

Get to Know Jazz Pharmaceuticals Better

Breaking Down Jazz Pharmaceuticals's Financial Performance

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.53%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Jazz Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 17.56%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Jazz Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 4.62%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Jazz Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 1.57%. This signifies efficient management of assets and strong financial health.

Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.51.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.